	US 11,773,372 B2
	Veto cells generated from memory T cells
Yair Reisner, Tel Aviv-Jaffa (IL); Noga Or-Geva, Rehovot (IL); Rotem Gidron Budovsky, Rehovot (IL); Esther Bachar-Lustig, Rehovot (IL); Assaf Lask, Rehovot (IL); and Sivan Kagan, Rehovot (IL)
Assigned to Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed by Yeda Research and Development Co. Ltd., Rehovot (IL)
Filed on Mar. 25, 2021, as Appl. No. 17/211,863.
Application 17/211,863 is a continuation of application No. 16/313,486, granted, now 10,961,504, previously published as PCT/IL2017/050716, filed on Jun. 27, 2017.
Claims priority of provisional application 62/354,950, filed on Jun. 27, 2016.
Prior Publication US 2021/0214687 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C12N 5/00 (2006.01); A61K 35/12 (2015.01)

CPC C12N 5/0637 (2013.01) [A61K 35/17 (2013.01); A61K 39/001 (2013.01); C12N 5/0087 (2013.01); A61K 2035/122 (2013.01); A61K 2039/5158 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2502/1121 (2013.01)]

21 Claims

1. A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, said cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, the method comprising:

(a) providing a population of T cells comprising at least 70% memory T cells;

(b) contacting said population of T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and

(c) culturing said cells resulting from step (b) in the presence of cytokines in an antigen free environment so as to allow proliferation of cells comprising said Tcm phenotype, thereby generating the isolated population of non-GvHD inducing cells.